512 results on '"Taniguchi, Cullen M."'
Search Results
152. Pancreatic cancer intratumoral microbiome and characteristics within paired patient samples.
153. A pilot course of intensive training in radiation biology and physics for oncologists in sub-Saharan Africa.
154. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer
155. Abstract 3746: Fasting in mice enables abdominal radiation dose escalation in the setting of pancreatic cancer by mitigating small intestinal toxicity
156. Abstract 3745: Mechanisms of HIF2-mediated small intestine radioprotection
157. Abstract 1402: Single cell transcriptomic profiling ofex vivotumoroid models reveal therapeutic vulnerabilities of pancreatic ductal adenocarcinoma
158. Adaptive Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4419 in pancreatic cancer.
159. Outcomes and patterns of failures after hypofractionated radiation therapy for intrahepatic cholangiocarcinoma.
160. Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer
161. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
162. The effect of IMRT on acute toxicity in patients with gastric cancer treated with preoperative chemoradiation.
163. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma
164. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma
165. Abstract 4164: Fasting protects mice from lethal radiation by promoting small intestinal stem cell survival
166. Abstract 2599: Circulating nucleic acids as biomarkers of prognosis and chemorefractory status in metastatic pancreatic cancer
167. Abstract 979: EGLN inhibition reduces gastrointestinal radiation toxicity and improves survival in a murine model of locally advanced pancreatic cancer
168. Dose Escalation for Locally Advanced Pancreatic Cancer: How High Can We Go?
169. Single Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
170. Chiral induction in cyclopentyl-derived 1,3- meso-diesters: enantioselective hydrolyses with electric eel acetylcholinesterase
171. Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation
172. Mitochondrial Fusion Suppresses Pancreatic Cancer Growth via Reduced Oxidative Metabolism
173. CEA as a pharmacodynamic biomarker for metastatic anal cancer.
174. Lymphopenia and outcomes of patients with unresectable hepatocellular carcinoma treated with radiotherapy.
175. Effect of stereotactic radiation (SBRT) on survival in a preclinical model of spontaneous pancreatic cancer with induction gemcitabine/nab-paclitaxel.
176. A prospective biomarker trial of microbiome, immune, and genomic markers as predictors of radiation response in anal squamous cell carcinoma.
177. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy
178. The Gut and Cervical Microbiome Promote Immune Activation and Response to Chemoradiation in Cervical Cancer
179. EGLN Inhibition Reduces Gastrointestinal Radiation Toxicity and Improves Survival in a Murine Model of Locally Advanced Pancreatic Cancer
180. Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?
181. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC
182. Tumor interface stability on CT imaging is an early marker of response to cytotoxic therapy in pancreatic ductal adenocarcinoma.
183. Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia
184. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism
185. Divergent Regulation of Hepatic Glucose and Lipid Metabolism by Phosphoinositide 3-Kinase via Akt and PKCλ/ζ
186. Suppression of PGC-1α Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma
187. PHD Inhibition Mitigates and Protects Against Radiation-Induced Gastrointestinal Toxicity via HIF2
188. The Phosphoinositide 3-Kinase Regulatory Subunit p85 Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling
189. Radiation-induced bone loss in mice is ameliorated by inhibition of HIF-2α in skeletal progenitor cells
190. Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials.
191. Critical nodes in signalling pathways:insights into insulin action
192. Dosimetric Analysis of Organs at Risk During Expiratory Gating in Stereotactic Body Radiation Therapy for Pancreatic Cancer
193. Intestinal HIF-2 to protect against radiation-induced gastrointestinal syndrome.
194. Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway
195. The Phosphoinositide 3-Kinase Regulatory Subunit p85α Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling
196. ChemInform Abstract: Chiral Induction in Cyclopentyl-Derived 1,3-meso-Diesters: Enantioselective Hydrolyses with Electric Eel Acetylcholinesterase.
197. ChemInform Abstract: A Two-Step Procedure for the Conversion of α,β-Unsaturated Aldehydes into γ-Azido-α,β-Unsaturated Nitriles.
198. Erratum: New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure
199. The p85α Regulatory Subunit of Phosphoinositide 3-Kinase Potentiates c-Jun N-Terminal Kinase-Mediated Insulin Resistance
200. Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and necdin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.